Oxcarbazepine
1
Reactions 1089 - 18 Feb 2006 Oxcarbazepine Thrombocytopenia: case report A 63-year-old woman developed thrombocytopenia during treatment with oxcarbazepine [therapeutic indication not clearly stated]. The woman, who had been hospitalised with paranoid ideation and increasingly disorganised behaviour, and had received a number of neuropsychotherapeutics, continued to be withdrawn and isolated. Oxcarbazepine 300mg twice daily was then added to her ongoing treatment with aripiprazole and venlafaxine and she showed an improvement in her mood and energy levels. After some days, she developed a low-grade fever and her platelet count had decreased to 208 000/µL [time to onset not stated] from 300 000/µL (normal 150 000–400 000). Daily monitoring showed a continued decrease in her platelet count; her platelet count was 110 000 and 18 000/µL on the seventh and tenth days of her treatment, respectively. The decrease in her platelet count was attributed to oxcarbazepine treatment. Oxcarbazepine was discontinued and, 4 days later, the woman’s platelet count had increased to 250 000/µL and, 3 days later, it had normalised. Author comment: "A cause-and-effect relationship between oxcarbazepine and thrombocytopenia is being postulated because a previously normal blood profile became abnormal without any other change in pharmacotherapy or medical causes. This abnormality also corrected itself when the offending agent was discontinued." Mahmud J, et al. Oxcarbazepine-induced thrombocytopenia. Psychosomatics 47: 73-74, No. 1, Jan-Feb 2006 - USA 801033735 1 Reactions 18 Feb 2006 No. 1089 0114-9954/10/1089-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Oxcarbazepine
Reactions 1089 - 18 Feb 2006
Oxcarbazepine
Thrombocytopenia: case reportA 63-year-old woman developed thrombocytopenia during
treatment with oxcarbazepine [therapeutic indication notclearly stated].
The woman, who had been hospitalised with paranoidideation and increasingly disorganised behaviour, and hadreceived a number of neuropsychotherapeutics, continued tobe withdrawn and isolated. Oxcarbazepine 300mg twice dailywas then added to her ongoing treatment with aripiprazole andvenlafaxine and she showed an improvement in her mood andenergy levels. After some days, she developed a low-gradefever and her platelet count had decreased to 208 000/µL [timeto onset not stated] from 300 000/µL(normal 150 000–400 000). Daily monitoring showed acontinued decrease in her platelet count; her platelet countwas 110 000 and 18 000/µL on the seventh and tenth days ofher treatment, respectively. The decrease in her platelet countwas attributed to oxcarbazepine treatment.
Oxcarbazepine was discontinued and, 4 days later, thewoman’s platelet count had increased to 250 000/µL and,3 days later, it had normalised.
Author comment: "A cause-and-effect relationshipbetween oxcarbazepine and thrombocytopenia is beingpostulated because a previously normal blood profile becameabnormal without any other change in pharmacotherapy ormedical causes. This abnormality also corrected itself whenthe offending agent was discontinued."Mahmud J, et al. Oxcarbazepine-induced thrombocytopenia. Psychosomatics 47:73-74, No. 1, Jan-Feb 2006 - USA 801033735
1
Reactions 18 Feb 2006 No. 10890114-9954/10/1089-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
